Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 10 of 11
Investments and investor services
FTSE 100 shares had a good start to the fourth quarter, helped by good manufacturing data and hopes that the pound's sharp fall on Monday will help exporters
It was better news for the miners which have rallied since June’s EU referendum
The trial met the met the primary endpoint of a better performance that the single medicines alone said the pharma
Exane BNP Paribas downgrades online grocer after it warned of margin pressure from rivals
Jefferies upgraded the health giant to a 'buy' recommendation
Investments and investor services
London shares ended lower on Monday after comments from Fed official Dennis Lockhart added to the chorus of central bankers calling US rates higher next week
Karl Hård, formerly at pharma titan AstraZeneca PLC has joined executive management as head of investor relations and corporate communications
This week AstraZeneca announced a next-generation asthma drug that would see it locking horns with fellow pharma giants over treatments already out there.
The new drug reduced wheeze, cough, chest tightness and shortness of breath
London shares closed sharply higher on Friday and more than erased the previous session’s losses as two unlikely bedfellows – tobacco and pharma stocks – led the gains alongside a rebound by miners which had a difficult week
An unlikely combination of tobacco and drugs stocks are driving the top-share index's advance
London stocks closed higher on Friday, feeding off the initial optimism of Wall Street investors over comments from the US central bank’s chief Janet Yellen, while 15-month highs for zinc prices made miners dominate the skyline
FTSE 100 added 8 to 6,825 and the FTSE AIM 0.4% to 792.5
Archive
Here we put the spotlight on Friday's market movers
London shares closed lower on Thursday, nestled in negative territory throughout the session, as investors turned wary ahead of Fed chair Janet Yellen’s speech at Jackson Hole on Friday and pharma stocks were singed by Hillary Clinton’s pro
Mylan reacted by announcing plans to boost access to the product by expanding already-existing programs for patients who face what’s called out-of-pocket expenses.
Hilary Clinton took aim at one US drugs company - yet the shock waves were felt here in London.
The deal is for its late-stage small molecule antibiotics business and involves three already-approved antibiotics - Merrem, Zinforo and Zavicefta - and two drugs in clinical trials (ATM-AVI and CXL).
A scrum to acquire US cancer drug company Medivation was emerging on Wednesday after reports that Merck, Pfizer and Gilead Sciences were among at least five pharmaceutical companies expressing an interest
London blue-chip stocks closed at their session nadir on Tuesday and their lowest since Thursday as a miners’ rally failed to buttress the main line ticker as oil prices hit six-week highs in Europe
Blue-chips are becalmed after opening lower, though mining stocks continue to provide some cheer
The top seven Footsie performers are all miners, with Antofagasta topping the list after its half-year update
Astra’s announcement was the second disappointing outcome for NSCLC sufferers in the space of a week.
Sound Energy shares have already climbed more than 250% since early July, but according Cantor's upgraded target there remains plenty of upside.
Archive
London's blue-chip stocks ended lower on Thursday after a session spent mostly suspended beneath the previous closing level as investors sought safer haven in UK government bonds, or gilts
The FTSE 100 Index was 6.56 points adrift at 6,743.87 in lunchtime trading
New products saw an 8% sales rise to US$3.7bn with new heart disease drug Brilinta especially strong
Archive
The FTSE 100 Index was 3.2 points adrift at 6,747.24 in early trading
To misquote Prince, it’s just another frantic Thursday with around one-sixth of the FTSE 100 companies set to update the market.
Brokers forecast rival interest after Galenica snaps up Relypsa for US$1.53bn
Drug giant said a phase III trial of Tagrisso had met its primary endpoint
London's blue chips shed a couple of points at the close after gains earlier
Investments and investor services
The Footsie fell 0.18 points to 6682.68 in early trading
London shares closed on Monday at their highest level in exactly eleven months, feeding off Wall Street’s record levels
The FTSE 100 Index climbed 55.17 points while M&A talk involving AstraZeneca re-emerged
London’s FTSE 100 index on Wednesday closed above “Brexit” crisis levels for the first time since the morning of the In-Out European Union referendum polling last Thursday
Archive
Broadcaster ITV was downgraded, as was airline group IAG
Investments and investor services
That's it from us for a very volatile Friday, more Brexit reaction to follow on Monday.
Astra said its findings differed from those of the US CDC
British drug group said Aspen will acquire commercialisation rights to its anaesthetic medicines outside the US
The FTSE 100 Index closed 24.02 points up at 6209.63
British drug group acquires exclusive US rights to Zurampic
Archive
News from drugs giant Astra this morning was like the proverbial curate’s egg: good in parts.
Drug company says Lynparza fell short of hopes in phase three trial
Archive
Bookmaker William Hill has its target lowered by City broker Canaccord.....
Shares in London fall back late on despite solid start
Archive
Also, Tullow Oil, Astra Zeneca, Next, Armadale Capital, Eland Oil...
UK drug giant set to focus on cancer drugs but declines to comment on Medivation takeover speculation
French drug group offers US$9.3bn for prostate cancer specialist
AstraZeneca releases first quarter results on Friday, the schedule also includes Shire, BA owner International Consolidated Airlines, and Royal Bank of Scotland Group.
UK shares ended the day in similar fashion as they begun, with big caps outshining smaller stocks.
After Silicon Valley giants Alphabet and Microsoft disappointed this week, next Tuesday brings Apple Inc’s second-quarter earnings.
The FTSE 100 Index closed 9.77 points higher at 6,353
AstraZeneca has reportedly held talks with San Francisco-based Medivation
Small caps pare losses but Footsie drops nearly 20 points
Indices drop after Iran's absence at talks scuppers hopes of price freeze
Archive
Credit Suisse is bullish on consumer goods giant Unilever PLC ahead of first quarter results on April 14 and has ramped up the target price.
Lilly has made what’s known as a milestone payment following progress in developing a treatment called AZD3293 for early stage Alzheimer's disease.
Investments and investor services
Throughout the day Botswana Diamonds and Cyan Holdings competed to be the biggest riser on the day.
Not for the first time has the ambitious and acquisitive pharmaceutical behemoth Pfizer has been upset at the merger altar, but with its Allergan deal under threat, the company may well step back and assess shareholder value
Archive
PureTech Health told investors it had expanded its focus on microbiome-based interventions
Drug group said blood-thinning treatment missed targets for reducing repeat stroke and heart attacks
Lung drug developer says tests showed success in treating idiopathic pulmonary fibrosis
Archive
Broker Jefferies has cut its rating on drugs giant AstraZeneca PLC to 'hold' from 'buy' saying there's a lack of catalysts in 2016 to re-rate shares.
Cantor now rates RedX as a ‘buy’, and with a 105p target the broker sees some 150% upside to the current price of 41.5p.
Archive
US heavyweight Jefferies looks at global pharma today and downgraded Glaxo and AstraZeneca...
Archive
Footsie was buoyed by a good start to the week;s trading on Wall Street
FTSE 100 climbed 76 points to 6,026 despite a tough day for the pound
Miners lead the march of the blue-chips while among the small caps it is more a case of the salsa
Drug group gets "breakthrough therapy" designation for durvalumab in the US
Investments and investor services
The FTSE 100 Index rose in early trading after the Dow Jones Industrial Average closed 223 points ahead
A whisper to a scream ... rumors of another big pharma merger are gaining volume
Archive
Resource stocks were back in favour big-time today, helped by a softer US sollar
The FTSE 100 Index was 56.86 points up at 5894 at lunchtime
Investments and investor services
The FTSE 100 Index gained 64.07 points to 5901 in early trading
AstraZeneca is on a downer after it warns revenue and profits will be lower this year than last but Shell keeps going well
Drug group forecast total 2016 revenue and core EPS to decline in low to mid-single digit percentage terms
After BP's results on Tuesday, which took the market by surprise, traders will undoubtedly be anxious about Shell's figures on Thursday at a time when the oil market is in turmoil.
Big oil and big pharma will wrestle for the limelight. On the economic front, the big events are the Bank of England's interest rate decision and US non-farm payrolls.
Archive
BAE Systems, Burberry, Next, Smith & Nephew, AstraZeneca and Britvic are all in the broker spotlight on Tuesday.
Two drug groups to merge to create a rare disease specialist
Professor Malcolm Young is stepping down as chairman but will remain in his role as chief executive.
Archive
Shares in drug giants Glaxo and Shire should stay in fine heath this year, Barclays says
Archive
While it is unlikely the Footsie will finish the year in credit, three more days of 60 points gains will see it go close
Flood damage in the north of England could see a lot of work coming the way of Britain's house builders
The strength of pharma stocks more than outweighed the softness of commodities plays early doors
There has been plenty of deal-making in the UK and record merger and acquisition (M&A) activity in the USA.
Archive
Miners, Restaurant Group, AstraZeneca, Bovis
The Fed and pharma world were among the trending stories of the day.....
Leading the way on the index was Standard Chartered
Investments and investor services
In the UK, the FTSE100 had that feel-good feeling following the Fed hike
Drug group is buying 55% interest in Acerta Pharma
The FTSE100, which is down around 7.5% on the year, rose almost 1%, or 59 points, to 6,076 by lunch.
FTSE 100 Index rose as investors brace for the first US interest rise in almost a decade.
